[EN] C-SUBSTITUTED TRICYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS [FR] DERIVES D'ISOXAZOLINE TRICYCLIQUES SUBSTITUES SUR LE CARBONE, ET LEUR UTILISATION COMME ANTIDEPRESSIFS
[EN] C-SUBSTITUTED TRICYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS [FR] DERIVES D'ISOXAZOLINE TRICYCLIQUES SUBSTITUES SUR LE CARBONE, ET LEUR UTILISATION COMME ANTIDEPRESSIFS
C-SUBSTITUTED TRICYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS
申请人:JANSSEN PHARMACEUTICA N.V.
公开号:EP1537124B1
公开(公告)日:2007-08-01
US7465741B2
申请人:——
公开号:US7465741B2
公开(公告)日:2008-12-16
[EN] C-SUBSTITUTED TRICYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS<br/>[FR] DERIVES D'ISOXAZOLINE TRICYCLIQUES SUBSTITUES SUR LE CARBONE, ET LEUR UTILISATION COMME ANTIDEPRESSIFS
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2004016621A1
公开(公告)日:2004-02-26
The invention concerns substituted tricyclic isoxazoline derivatives according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisoxazoline , dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on the phenylpart of the tricyclic moiety with at least one radical that is attached to the phenyl radical by a carbon-carbon bond as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherin all variables are defined in Claim 1. (I) The compounds have surprisingly been shown to have selective serotonine (5-HT) reuptake inhibitor activity in combination with additional α2-adrenoceptor antagonist activity and show a strong anti-depressant and/or anxiolytic activity and/or antipsychotic and/or a body weight control activity without being sedative. Also, in view of their selective serotonine (5-HT) reuptake inhibitor as well as α2-adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.